Kaftrio (Tezacaftor, Elexacaftor, Ivacaftor)

The combination contains two CFTR correctors—tezacaftor and elexacaftor—that help the defective CFTR protein fold correctly and reach the cell surface. Ivacaftor, a CFTR potentiator, then enhances the opening of the channel, together restoring chloride transport across epithelial cells.

The dosing regimen for Kaftrio is individualized by the prescribing healthcare professional based on the patient’s age, weight, and clinical condition. The prescriber determines the number of tablets and timing, and patients should follow the exact instructions provided on the prescription label.

Safety data for Kaftrio during pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against possible risks and discuss these considerations with the patient. Women who are pregnant, planning to become pregnant, or breastfeeding should consult their physician before using the medication.

To request Kaftrio, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then respond with pricing, availability, shipping details, and any necessary import documentation.

The primary alternative is the lumacaftor/ivacaftor combination (Orkambi) or the tezacaftor/ivacaftor combination (Symdeko). Kaftrio adds a second corrector, elexacaftor, which provides broader coverage of CFTR mutations and generally yields greater improvements in lung function and reduced exacerbations for patients with at least one F508del allele.

Kaftrio tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original blister pack, protect it from moisture and direct sunlight, and store out of reach of children.

Kaftrio is taken orally as a tablet. Patients should swallow the tablet whole with water, with or without food, following the dosing schedule prescribed by their healthcare provider.

Serious risks include significant liver injury (marked elevation of liver enzymes or bilirubin), development of cataracts, severe allergic reactions such as anaphylaxis, and rare pulmonary hemorrhage. Patients should report any signs of jaundice, visual changes, difficulty breathing, or unusual bleeding to their clinician promptly.

Kaftrio is contraindicated in individuals with a known hypersensitivity to any of its components, and in patients with severe hepatic impairment. Caution is also advised for those with a history of cataracts or liver disease, and it should be used only under medical supervision.